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1ABSTRACT
CD151 as a potential molecular marker of cholangiocarcinoma stem cells
Tae Joo Jeon
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Si Young Song)
Cancer stem cells are currently hypothesized to be responsible for 
tumorigenesis, metastasis, recurrence, and chemoresistance in the various types 
of cancer.
CD151 is a member of the transmembrane 4 superfamily, which enhances cell 
motility, invasion, and metastasis of cancer cells. In intrahepatic 
cholangiocarcinoma, overexpression of CD151 associated with c-Met is
implicated in invasion and metastasis, which result in poor prognosis. However, 
there are few studies that focus on CD151 in cholangiocarcinoma, and the role 
of CD151 in cancer stem cells, including cholangiocarcinoma stem cells, which 
have hardly been documented.
The aim of this study is therefore to characterize the role of CD151 in 
cholangiocarcinoma stem cell. 
To evaluate cholangiocarcinoma stem cell, the author prepared cancer stem 
like cells using sphere cultivation (SNU-245, SNU-1196). A cDNA microarray 
was used to gain up-regulated genes between tumorsphere and biliary 
carcinoma.  The expressions of stemness genes and the proteins related to 
c-Met and Epithelial Mesenchymal Transition (EMT) were evaluated through 
RT-PCR and western blot to find if tumorsphere has characteristics of stem cell.   
2Expression of CD151 was compared between adherent cells of SNU-1196 and 
tumorsphere. To evaluate the role of CD151 in cholangiocarcinoma stem cells, 
CD151 knockdown was done by CD151 siRNA in SNU-1196 cells and then
sphere formation and cytotoxicity assay were performed. In order to evaluate 
the mechanism of CD151, c-Met, EMT pathway related molecules, β-catenin, 
and Oct 4 were evaluated through western blot. Proliferation and metastatic 
capabilities were also evaluated after transfection of CD151 siRNA in 
SNU-1196.
As a result, CD151 gene was highly up-regulated in both tumorspheres and 
biliary carcinoma on cDNA microarray. Cultivated tumorsphere had cancer 
stem cell-like properties, showing highly expressed Notch, Hedgehog, and Wnt 
pathway related to stem cells in RT-PCR. Expressions of the proteins that 
related to c-Met, PI3K, EMT pathway, β-catenin, and Oct 4 were more highly 
increased and CD151 was more highly expressed in tumorsphere than in 
adherent cells. 
After CD151 knockdown, tumorsphere formation was inhibited and 
chemoresistance was reduced. The expression of the molecules associated 
c-Met, PI3K, EMT pathways, β-catenin and Oct4 was reduced. Therefore, the 
characteristics of proliferation and migration were also reduced after 
transfection of CD151 siRNA in SNU-1196 cells. 
The author could suggest that CD151 was more expressed in 
cholangiocarcinoma stem-like cells and regulated self-renewal, chemoresistance, 
proliferation and metastatic capabilities. It might interact with c-Met and 
activate PI3K, EMT pathway, β-catenin, and Oct4. So, it would be a potential 
cholangiocarcinoma stem cell related marker and therapeutic target in the 
future. 
----------------------------------------------------------------------------------------
Key words: CD151, cholangiocarcinoma stem cell, c-Met
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Tae Joo Jeon
Department of Medicine
The Graduate School, Yonsei University
(Directed by Professor Si Young Song)
I. INTRODUCTION
Cholangiocarcinoma is a rare malignant cancer of the bile ducts which has 
poor prognosis.1 Although treatment is possible with a surgical approach, most 
cases are inoperable and cancer recurrence is frequent even after surgery. In 
addition, there is no effective drug treatment for advanced and recurrent 
cholangiocarcinoma.2,3 In modern medicine, these poor clinical outcomes are 
often attributed to cancer stem cells. This is a concept which has been proposed 
in the last decade and is known as the ‘cancer stem cell hypothesis’.4
Cancer stem cells are believed to have self-renewal, proliferation, and 
multilineage differentiation capabilities. They are hypothesized to be 
responsible for tumorigenesis, metastasis, recurrence, and chemoresistance and 
are considered to play an important role in the carcinogenesis of various types 
of cancer.5,6 Although many cancer stem cell markers have been reported in 
various solid tumors, few studies in this field have investigated 
cholangiocarcinoma stem cells. Furthermore, the role of cholangiocarcinoma 
stem cells in the pathogenesis of cholangiocarcinoma has not been fully 
understood. Recently, several reports have demonstrated the existence of 
cholangiocarcinoma stem cells.7,8 CD133, CD24, EpCAM, and CD44, along 
4with other adhesion molecules have also been reported as molecular markers of 
these stem cells.9-16 However, these markers are controversial and continue to be 
the subject of much debate.
CD151 protein is a member of the transmembrane 4 superfamily, also known 
as the tetraspanin family.17 It is a cell surface glycoprotein that is known to form 
complexes with integrins and other transmembrane 4 superfamily proteins. 
CD151 is highly expressed in epithelial and endothelial cells18,19 and plays a 
role in the regulation of cell development, activation, growth, and motility. It 
also enhances cell motility, invasion, and metastasis of cancer cells, especially 
in colon cancer and fibrosarcoma cells.20 In hepatocellular carcinoma, CD151 
was associated with invasiveness, and CD151 or a combination of 
CD151/c-Met were independent prognostic factors.21 Dysregulation of CD151 
has been observed in many cancers, and overexpression of CD151 was 
indicative of poor prognosis in hepatocellular carcinoma and non-small lung, 
colon, pancreatic, esophageal, gastric, breast, and endometrial cancer.22-29 In 
intrahepatic cholangiocarcinoma, CD151 and c-Met were independent 
prognostic markers.30
CD151 interacted laminin-binding integrins α3β1, α6β1, α6β4 and α7β1 in 
cells in culture and in vivo.31 CD151 regulated tumor cell migrations through 
α3β1 and α6β4 on laminin-532 and promoted cancer cell metastasis via integrins 
α3β1 and α6β1.33,34 CD151 enhanced c-Met signaling pathway through integrin 
β4 and contributed to tumor cell proliferation and invasive growth.35 In 
pancreatic ductal adenocarcinoma, CD151, c-Met, and integrin α3/α6 were also 
overexpressed and showed poor prognosis.24  High expression of CD151 and 
α6 activated epithelial-mesenchymal transition (EMT) through PI3K/APK 
pathway and resulted in invasiveness of hepatocellular carcinoma.36 CD151 also 
promoted neoangiogenesis and progression of hepatocellular carcinoma by 
modulating matrix metalloproteinase 9 through PI3K/Akt/GSK-3β/SNAIL 
pathway.28 However, the studies mentioned here remain among the few to 
5investigate CD151 in cholangiocarcinoma, and the role of CD151 in 
cholangiocarcinoma stem cells, has not yet been elucidated.
The aim of this study was to characterize the role of CD151 in 
cholangiocarcinoma stem cell. Considering the lack of study regarding CD151 
in cholangiocarcinoma stem cells, the comprehension of the CD151 function is 
important for understanding cancer mechanism and advancement of current 
treatment. Finally, the development of a targeted therapy for CD151 or related 
molecules may improve future survival rates for patients with this disease. 
II. MATERIALS AND METHODS
1. cDNA microarray analysis
cDNA microarray was performed to gain up-regulated genes in tumorsphere than 
in adherent cells. The experiment was performed with cells derived from 
tumorsphere and adherent cells of biliary carcinoma cell line. RNA was extracted 
by using RNeasy mini kit (Qiagen, Valencia, CA, USA), and RNA quality was 
verified by A260/A280 ratio and agarose gel electrophoresis with resolution of 
distinct 28s and 18s. The microarray procedures were carried out following the 
manufacturer’s protocols. The complementary DNA (cDNA) microarray analysis 
was performed by Digital Genomics (Seoul, Korea). Using 6 ㎍ of template, 
double stranded cDNA was prepared, after which amplification and biotin-labeling 
(IVT labeling kit; Affymetrix, Santa Clara, CA, USA) were performed. The 
labeled cRNA was fragmented and used in the hybridization reaction to
GeneChip@ probe array HG U133 plus 2.0 version high-density oligonucleotide 
array (Affymetrix, Santa Clara, CA, USA). Microarrays were then washed in a 
6GeneChip Fluidics Station 450 (Affymetrix, Santa Clara, CA, USA) and scanned 
using a GeneChip Array Scanner 3000 7G (Affymetrix, Santa Clara, CA, USA).
Expression data were generated using Affymetrix Expression Console software 
version 1.1 using MAS5 algorithm normalization. Expression intensity data in 
CEL file were normalized with the MAS5 algorithm to reduce noise. Probe sets 
that were not identified as ‘‘present’’ by the MAS5 detection call in more than 
50% of the samples in at least 1 sample group were removed. Genes regulated 
more than 1.2 fold were taken into consideration. Each individual chip analysis 
was performed twice with duplicated independent total RNA samples. Human 
gallbladder cancer chip data which was already analyzed by cDNA microarray 
compared with normal human gallbladder tissue in our lab was used. The 
gallbladder cancer genes were selected when expressed more than two times than 
normal gallbladder (p<0.01) and related to the development. The molecules 
produced by selected genes should be located in the cell membrane and secretory 
type. With using all the results, the author analyzed the commonly up-regulated 
genes in gallbladder cancer, SNU-245, and SNU-1196. 
2. Cell culture and sphere formation assay
Human biliary tract cancer cell lines: SNU-245 (common bile duct carcinoma), 
and SNU-1196 (hilar bile duct carcinoma), were purchased from the Korea Cell 
Line Bank (KCLB, Seoul, Korea). NIH-3T3 mouse embryonic fibroblast cell line 
was obtained from the American Type Culture Collection (ATCC, VA, USA). 
All cells were grown in RPMI 1640 medium (Invitrogen Gibco, NY, USA) 
supplemented with 10% fetal bovine serum (FBS; Hyclone, UT, USA), and were 
kept in a humidified incubator at 5% CO2 and 37°C. 
Single cell suspensions at a concentration of 1000 cells/mL were seeded onto 
76-well ultra-low attachment culture plates (Corning Inc., NY, USA) for the 
sphere formation assay, which was performed as described previously37. Sphere 
formation medium consisting of serum-free medium (SFM) supplemented with 
10 ng/mL epidermal growth factor (R&D Systems Inc., MN, USA), 10 ng/mL 
basic fibroblast growth factor (R&D Systems), 1 × insulin-transferrin-selenium 
(Invitrogen Gibco), 0.5% bovine serum albumin (BSA; Invitrogen Gibco), and 
0.5% FBS was used. As a control, cultured cells that were adherent were seeded 
onto culture dishes (Nalge Nunc Int, NY, USA) with sphere formation medium. 
3. Semiquantitative reverse-transcription polymerase chain reaction 
(RT-PCR)
The expression of CD151 was checked using RT-PCR. Total RNA was 
extracted from the cells using an RNeasy mini kit (Qiagen, CA, USA), and 
complementary single-strand DNA was synthesized using the Superscript II 
system (Invitrogen) according to manufacturer’s protocols. β-actin (ACTB) was 
used as a reference housekeeping gene. The primers used are listed in Table 1.
After transfection of the siRNA into SNU-1196 cells, RT-PCR analysis was 
performed at 30 and 96 h post-transfection.
8Table 1. Primer Sequences Used For RT-PCR
Gene Sense Antisense
Notch3 ATGGTGGGAACTAAACACAGCT ATGACCCTGGAGGAAGCACA
Hes1 GTGCTGTCTGGATGCGGAGT GAACACTCACACTCAAAGCCC
Jagged1 CTCAATTACTGTGGGACTCATCA GAACACTCACACTCAAAGCCC
Ihh CCTGAACTCGCTGGCTATCT AATACACCCAGTCAAAGCCG
Gli1 AGAGTCCAGGGGGTTACATA AGAGTCCAGGGGGTTACATA
Nanog ACTGTCTCTCCTCTTCCTTCCT AGAGTAAAGGCTGGGGTAGGTA
Oct4 GTGGAGGAAGCTGACAACAA AGCAGCCTCAAAATCCTCTC
PTEN GGACGAACTGGTGTAATGAT CAGACCACAAACTGAGGATT
FZD7 CCAACGGCCTGATGTACTTT GCCATGCCGAAGAAGTAGAG
β-catenin GTATGAGTGGGAACAGGGATTT CCTGGTCCTCGTCATTTAGC
C-met CAATGTGAGATGTCTCCAGC CCTTGTAGATTGCAGGCAGA
Snail
AAGCTTCCATGGCGCGCTCTTT
CCTCGTCAGGAAGCCC
GGATCCTCAGCGGGGACATCCT
GAGCAGCCGGACTCTTG
Vimentin GAGAACTTTGCCGTTGAAGC GCTTCCTGTAGGTGGCAATC
CD90 GACCCGTGAGACAAAGAAGC ACTGTGACGTTCTGGGAGGA
CEACAM1 ATACCTGCCACGCCAATAAC TTATGCTGAGGGTGGTGTTG
CD151 CTCCCCGGACATACTCTCTG GTCAGAGCTCACCTGGCTTC
CD104 TCTACACGGACACCATCTGC GGGCAGTCCTTCTTCTTGTG
β –actin GGCATCCTCACCCTGAAGTA GGGGTGTTGAAGGTCTCAAA
4. Transfection of CD151 siRNA in SNU-1196
In order to evaluate the function of CD151, knockout cells were obtained by the 
transfection of CD151 small interfering RNA (siRNA) (sc-42829; Santa Cruz 
Biotechnology, CA, USA) composed of a pool of three target specific siRNAs, 
and a control siRNA-A (sc-37007; Santa Cruz Biotechnology) at a concentration 
of 33 nM into the cells using Lipofectamine RNAiMAX transfection reagent 
(Invitrogen). 
95. Western blot analysis. 
To further analyze CD151 expression, western blotting was carried out for the 
cells. Cells were lysed in lysis buffer containing 70 mM β-glycerophosphate (pH 
7.2), 0.6 mM sodium orthovanadate, 2 mM MgCl2, 1 mM ethylene glycol 
tetraacetic acid (EGTA), 1 mM dithiothreitol (DTT), 0.5% TritonX-100, 0.2 mM 
phenylmethanesulfonylfluoride (PMSF), and 1× complete protease inhibitor 
(Roche Applied Science, NJ, USA). Protein (20 µg) was loaded onto and 
resolved on SDS-polyacrylamide gel and then transferred to polyvinylidene 
difluoride (PVDF) membranes (Immobilon-P, Millipore, Bedford, MA). The 
membranes were blocked in 5% (w/v) non-fat dry milk and probed with the 
following primary antibodies: rabbit anti-Met polyclonal antibody (PAb), rabbit 
anti-phospho-AKT PAb, rabbit anti-phospho-GSK3 PAb, rabbit anti-SNAIL PAb, 
rabbit anti-Oct4 PAb, mouse anti-CD151 MAb, rabbit anti-Integrin β4 PAb, 
mouse anti-N-cadherin Mab (Abcam plc., MA, USA), rabbit anti-Occludin PAb,
mouse anti-β-catenin MAb, rabbit anti-AKT PAb, rabbit anti-ERK PAb, rabbit 
anti-phospho-ERK PAb, and mouse anti-GAPDH MAb (Santa Cruz 
Biotechnology Inc.). Immunoblots were developed with West Pico 
Chemiluminescent Substrate (Thermo Scientific, IL, USA). The dilution ratio of 
all primary antibodies was 1:1000. 
6. Proliferation assay
SNU-1196 cells transfected with CD151 siRNA or control siRNA were seeded 
at 103 cells/well in 96-well plates and cultured in a CO2 incubator at 37℃ for 3 
days. After 3 days, 100µl MTT solution (0.5 mg/ml in media) was added per 
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each well and cells were incubated for 3 hours at 37°C. Next, the solution was 
discarded and 100µl DMSO was added to the cells. Plates were shaken for 30 
minutes and absorptions were measured at 570 nm using Tilter-Tech 96-well 
multiscanner (Becton Dickinson, Heidelberg, Germany).
7. Cell migration assay
Forty-eight hours after the transfection of CD151 siRNA into SNU-1196, cell 
migration assays were performed in 24-well transwell plates (8 µm; CoStar, MD, 
USA), seeded at a concentration of 1 × 104 cells/well in serum free RPMI 
medium in the upper chambers. The lower chambers were filled with conditioned 
media derived from NIH3T3 cultures. After 24 h, migrated cells were fixed in 
5% glutaraldehyde/PBS and stained with toluidine blue for cell-number scoring 
and cells were counted using light microscopy. Migrated cells were defined as 
the cells that had passed into the lower layer, and experiments were performed in 
triplicate for this assay.
8. Cytotoxicity assay 
The cytotoxicity assay of gemcitabine (Eli Lilly Korea, Seoul, Korea) was 
assessed with a 3-(4,5-dimethylthiazol-2yl)-2,5-diphenyltetrazolium bromide 
(MTT; Sigma-Aldrich, Inc., St. Louis, MO). SNU-1196 cells transfected with 
CD151 siRNA or control siRNA were seeded at 103 cells/well in 96-well plates 
and cultured in a CO2 incubator at 37℃ for 24 hours. The next day, various 
concentrations of gemcitabine were added and incubated for 72 hours. Treated 
11
cells were incubated in 100µl MTT solution (0.5 mg/ml in media) for 3 hours. 
The solution was discarded and 100µl DMSO was added to each well. The 
absorbance of each well was measured at 570 nm using Tilter-Tech 96-well 
multiscanner (Becton Dickinson, Heidelberg, Germany).
9. Statistical analysis
All data were presented as means ± standard deviations. Statistical significance 
for the results of sphere forming, cytotoxicity, proliferation, and migration assay 
was determined using independent samples t test and one way ANOVA.
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III. RESULTS
1. CD151 gene was up-regulated in both tumorsphere and biliary carcinoma 
cells 
Up-regulated genes were obtained in tumorsphere of both SNU245 and 
SNU1196 cells comparing with adherent cells by cDNA microarray. Moreover, 
Gallbladder cancer chip data was also used to find commonly up-regulated genes 
between tumorsphere and biliary cancer cells. Four hundred sixteen genes were 
commonly up-regulated between SNU245 tumorsphere and gallbladder cancer 
cells. Two hundred fifty-five genes were also up-regulated in both SNU1196 
tumorsphere and gallbladder cancer cells. Sixty-one genes were highly expressed 
in all three groups (Figure 1-A). CD151 was confirmed as an up-regulated gene in 
all three groups (Figure 1-B). 
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A.
B.
Figure 1. cDNA microarray analysis. A. Upon the microarray data, the genes were 
selected if the expression level was greater than 1.2-fold (p<0.05). Sixty-one genes 
were highly up-regulated genes in all SNU-245, SNU-1196 tumorsphere, and 
gallbladder cancer. B. CD151 was confirmed as up-regulated genes in all three 
groups. 
2. The expression of CD151 was higher in tumorsphere than in adherent cells 
of biliary carcinoma cells 
Tumorsphere expressed higher mRNA levels of Notch3, Ihh, Gli1, FZD7, and 
β-catenin than adherent cells. Upon RT-PCR, the author confirmed that the 
Notch, Hedgehog, and Wnt signaling were activated in the tumorsphere. c-Met 
and Vimentin relating to the EMT pathway and CD90 known as liver cancer stem 
cell marker was also highly expressed in the tumorsphere (Figure 2-A). The 
14
c-Met pathway relating molecules such as c-Met and pAKT were highly 
expressed in the tumorsphere on western blot. EMT relating molecules such as 
snail and N-cadherin were also highly expressed in the tumorsphere (Figure 2-B). 
Based on these results, the author confirmed that the tumorsphere might have 
cancer stem-like properties.
The expression of CD151 was higher in the tumorsphere than in the adherent 
cells on both RT-PCR and western blot (Figure 2-A, B). 
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A.
B.
Figure 2. RT-PCR analysis (A) and western blot (B) in the adherent cells and the 
tumorsphere of the biliary carcinoma cell line, SNU-1196. A. Highly expression of 
mRNA molecules relating to Notch, Hedgehog, Wnt signaling, and EMT were 
seen in the tumorsphere. B. The molecules associated with c-Met and EMT 
pathways were highly expressed in the tumorsphere. RT-PCR and western blot
showed that the expression of CD151 was higher in the tumorsphere than in the 
adherent cells (A; adherent cells, SP; tumorsphere). 
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3. CD151 knockdown was confirmed in the biliary carcinoma cell line, 
SNU-1196, after transfection of CD151 siRNA
To elucidate the role of CD151 in cholangiocarcinoma stem cell, CD151 
knockdown was carried out by CD151 siRNA transfection. After transfection of 
the siRNA into SNU-1196 cells, RT-PCR analysis showed CD151 mRNA to be 
decreased at 30 and 96 h post-transfection. Furthermore, using western blotting, 
the expression of CD151 was inhibited at 48 and 72 h post-transfection (Figure 
3). 
A.
B.
Figure 3. CD151 expression after transfection of CD151 siRNA in SNU-1196. A.
RT-PCR results obtained at various post-transfection time points. The expression 
of CD151 mRNA was decreased at 30 and 96 h. B. Western blot of the SNU-1196 
cells lysate at various post-transfection time points. The expression of CD151 was 
decreased at 24 h and was strongly inhibited at 48 and 72 h.
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4. CD151 promoted tumorsphere formation and chemoresistance in
SNU-1196
Sphere formation and cytotoxicity assay were done to evaluate the role of 
CD151 in the cancer stem-like cells. 
Sphere formation assays were performed after transfection of control and 
CD151 siRNA into the SNU-1196 cell line to characterize the effects of CD151 
on cancer stem-like cells. On microscopy, tumorsphere formation was still 
observed after transfection of control siRNA (Figure 4-A, control siRNA), but 
was completely inhibited after transfection of CD151 siRNA (Figure 4-A, CD151 
siRNA). On counting, the number of tumorsphere was significantly decreased
after CD151 knockdown (Figure 4-B). Upon these finding, the author could 
suspect that CD151 might affect the self-renewal property of cancer stem-like 
cells. 
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A.
B.
Figure 4. Sphere formation assay of SNU-1196 after transfection of control and 
CD151 siRNA (OLYMPUS DP71 microscope × 5 magnifications). (B) The 
number of tumorsphere was markedly decreased after CD151 knockdown 
(*p<0.05).  
Cytotoxicity assay showed that the chemoresistance to gemcitabine was 
decreased after transfection of CD151 siRNA (Figure 5) into SNU-1196. As the 
dose of gemcitabine was increased, the number of the survived cells was more 
decreased in CD151 knockdown SNU-1196 cells than in the control group
(p<0.05). CD151 might also regulate the chemoresistance in the cancer stem like 
cells.   
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Figure 5. Cytotoxicity assay of SNU-1196 after transfection of control and CD151
siRNA. As the dose of gemcitabine was more increased, the number of survived
cells was more decreased after transfection of CD151 siRNA into SNU-1196 than 
in the control group (*p<0.05). Chemoresistance was more reduced in the CD151 
knockdown SNU-1196 cells.
5. CD151 interacted with c-Met, and activated PI3K and EMT pathway, and 
promoted β-catenin and Oct4 in SNU-1196
Previous results showed that CD151 was expressed in the cancer stem like 
cells and regulated the stemness and chemoresistance. In order to gain a more 
detailed insight into the effects of CD151 in cancer stem like cells, various 
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proteins were examined for their expression levels in the SNU-1196 cells by 
western blot at 72 h post-transfection of CD151 siRNA, based on the result of 
western blot in the tumorsphere. The expression of c-Met, pAKT, and pGSK3 
were decreased after CD151 knockdown. Both the c-Met signaling pathway and 
the PIK3 pathway were affected. The expression of β-catenin and Oct4 was also 
decreased after CD151 knockdown. EMT pathway-associated molecules such as 
Snail and N-cadherin were reduced after CD151 siRNA transfection into
SNU-1196 (Figure 6).
Upon these results, the author could postulate that CD151 interacted with c-Met 
and activated the PI3K pathway which promoted the EMT pathway and increased 
intra-nuclear β-catenin. Although the author does not understand the exact 
mechanism, increased β-catenin induced the Oct4. These molecules might be 
responsible for stemness, infiltration, and metastasis of cancer stem cells (Figure 
6, center box).  
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Figure 6. Summary of postulated pathway associated with CD151 and western 
blot assay in SNU-1196 after transfection of control and CD151 siRNA. CD151 
interacts with c-Met and activate subsequent pathway; PI3K pathway. Activated 
PI3K pathway induced the activation of EMT pathway and promoted β-catenin 
and Oct4 (solid lines; cell membrane, dot lines; nuclear membrane).
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6. CD151 promoted proliferation and migration of SNU-1196.
Because cancer stem cells also have proliferation and metastasis capabilities, the
author evaluated proliferation and migration assay after CD151 knockdown in 
SNU-1196 cells. 
Cellular proliferation was significantly decreased after transfection of CD151 
siRNA, compared with SNU-1196 cells and transfection of control siRNA. After 
transfection of control siRNA, cellular proliferation was reduced by 6% than 
SNU-1196 cells, but by 35% in CD151 knockdown cells (Figure 7, p<0.05). 
Figure 7. Proliferation assay of SNU-1196 after transfection of control and 
CD151 siRNA. Cell proliferation was reduced by 6% and 35% after transfection 
of control siRNA and CD151 siRNA respectively, compared with SNU-1196. 
Significance was tested by one way ANOVA test with * representing comparison 
with SNU-1196 and # with control siRNA with p value of <0.05.
.
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Migration assays were carried out 48 hours after transfection. The number of 
cells that migrated were markedly decreased after CD151 knockdown when 
counted under the microscope (Figure 7-A), and there was a statistically 
significant difference in the number of migrated cells between the control and 
CD151 knockdown cells (53.0±1.0 vs. 10.7±2.3 respectively, p<0.05, Figure 7-B). 
A
B
Figure 8. Migration assay of SNU-1196 after transfection of control and CD151 
siRNA. A. The migrated cells were markedly decreased after CD151 knockdown. 
B. The number of migrated cells, defined as cells that had relocated into the lower 
compartment of the transwell plates. Control siRNA; 53.0±1.0 migrated cells, 
CD151 siRNA cells; 10.7±2.3 migrated cells, *p<0.05.
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IV. DISCUSSION
The author used two biliary carcinoma cell lines, SNU-245 and SNU-1196
in this study. As the culture of the SNU-1196 cell line was relatively easy and 
it has been shown to have superior tumorsphere forming abilities and 
demonstrated greater stemness characteristics than the other cell lines, the 
author chose it for further analysis. Additionally, SNU-1196 holds mutant 
variants of a range of genes such as p53 and p16 and it was originally derived 
from Klatskin tumor of the hepatic duct and was indicative of poor prognosis. 
For proving that tumorsphere has cancer stem cells properties, the author
showed expression of ‘stemness gene’ was higher in tumorspheres than in
adherent cells.  Furthermore, the colony formation assay and in vivo
tumorigenecity experiments were also performed (Data not shown). As briefly
summarized, the results showed that the number of colonies was 80.3±2.1 and 
149.7±4.9 in adherent cells and tumorsphere of SNU-1196 respectively 
(p<0.05). 103 cells from both adherent cells and tumorspheres of SNU-1196 
were selected and implanted individually on the flank of nude mouse. After 12 
weeks from the transplantation, mice were sacrificed to access tumor volumes.
The size was 88 mm3 and 1,440 mm3 respectively (p<0.05). Based on these 
results, the author confirmed that the tumorsphere of SNU-1196 cells 
displayed a greater colony-forming efficiency, higher proliferative output, and 
greater tumorigenic capacity in vivo when compared with the adherent cells. 
cDNA microarray was performed in order to find the commonly 
up-regulated genes between tumorsphere and biliary cancer. Sixty-one genes 
were activated in SNU-245, SNU-1196 tumorsphere, and gallbladder cancer; 
CD151, Transgelin 2 (TAGLN), aldehyde dehydrogenase 3 family, memberA1
(ALDH3A1), fibroblast growth factor receptor 4 (FGFR4), chemokine
receptor 1 (CCR1), ATP-binding cassette, sub-family, member 1 (ABCA1), 
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v-erb-b2 erythroblastic leukemia viral oncogene homolog 2, 
neuro/glioblastoma derived oncogene homolog (ERBB2), aldehyde 
dehydrogenase 4 family, and memberA1 (ALDH4A1), etc. The genes were 
carefully selected considering the molecules were membranous, secretory and 
associated with cell’s development. Among them, the author gave attention to 
CD151 because some recent studies show that it was associated with motility, 
invasion, and metastasis in various carcinomas including cholangiocarcinoma, 
but there were hardly any studies about the role in cholangiocarcinoma stem 
cells. 
At first, the expression of CD151 was performed also in cancer tissues (Data 
not shown). The stain was definitively seen on the membrane of cells in 
cholangiocarcinoma tumor tissue. The expression of CD151 was also seen in 
both adherent and tumorsphere cells. However, CD151 expression was higher 
in tumorsphere cells than in adherent cells. Because we proved that 
tumorsphere had cancer stem-like properties by RT PCR of stemness gene, the 
colony formation assay and in vivo tumorigenecity experiments, tumorsphere 
formation and cytotoxicy assay were investigated after CD151 knockdown to 
evaluate the effect of CD151 on cancer stem-like cells. Since tumorsphere was 
inhibited and showed reduced chemoresistance after CD 151 knockdown, the 
author assumed that CD151 knockdown SNU-1196 cells showed decreased
cancer stem cell properties and CD151 might regulate cancer stem-like cells. 
In order to reveal how CD151 controls cancer stem-like cells, the author
took notice of c-Met and EMT pathways because both related proteins were 
more highly expressed in tumorspheres than in adherent cells (Figure 2-B). 
Infiltration and metastasis of cancer stem cells were also known to associate 
with c-Met and EMT pathway.  
CD151 was already known to make complex with integrin families and 
c-Met. For evaluation of immune complex with CD151, immunoprecipitation 
test was done. After immunoprecipitation was achieved by anti-CD151 
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antibody, integrin β4 and c-Met were expressed on the western blot (Data not 
shown). 
In cancer cells, activation of c-Met results in cell growth, differentiation, 
infiltration, and apoptosis via various signal pathways. RAS-MAPK,
PI3K-AKT, and STAT activity have been associated with c-Met activation.38,39
The Wnt/β-catenin pathway was also activated by interactions with 
HGF/c-Met complex.40 Overexpression of c-Met has been demonstrated to be 
related to poor prognosis in various cancers.39 Interestingly, a c-Met has been 
exhibited to be a pancreas stem cell marker in normal mouse tissue41 and has 
also been presented as a pancreatic cancer stem cell marker.42 As 
overexpression of c-Met and abnormal activation of c-Met/HGF has been seen 
in the benign proliferation of biliary epithelial cell and bile duct cancer, it was 
suspected as cause.43-45 Overexpression of c-Met is also linked to expression of 
EGFR and associated with poor prognosis in biliary cancer.46
In this study, expression of c-Met, pAKT, and pGSK3 was decreased after 
CD151 knockdown. EMT related molecules were also affected and the 
mesenchymal marker, expression of SNAIL and N-cadherin, was decreased 
after CD151 knockdown. Interestingly, the expression of molecules related to 
the RAS/MAPK pathway was not changed after transfection of CD151 siRNA 
(Data not shown). The author could guess that CD151 regulates
cholangiocarcinoma stem-like cells by c-Met and PI3K-AKT pathway. 
Expression of β-catenin and embryonic stem cell marker, Oct4 was also 
decreased after CD151 knockdown. A β-catenin and Oct4 were already known 
to be associated with cancer stem cells. As one study suggested that Wnt/
β-catenin regulated lung cancer stem cell through Oct4 in lung cancer A549 
cells,47 the author could presume that CD151 might control 
cholangiocarcinoma stem-like cells through β-catenin and Oct4. As another, a 
different study showed that Oct4 controlled colorectal cancer metastasis 
through EMT pathway,48 the result of EMT related molecules and Oct4 in this 
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study was notable. Although the author could not explain the exact function 
and interaction of these molecules, the author could guess CD151 regulate 
cholangiocarcinoma stem-like cells through c-Met, PI3K, EMT pathway, 
β-catenin and Oct4.
For the evaluation of the effect of CD151 on the proliferation and metastasis 
of cholangiocarcinoma, proliferation and migration assay were performed after 
CD151 knockdown. As expected, proliferation and migration was significantly 
decreased after transfection of CD151 siRNA into SNU-1196. Interestingly, 
one study shows that CD151 did not affect the proliferation of prostate cancer 
cells and promoted migration and invasion only.49 However, the results of this 
study showed that CD151 might regulate the proliferation and metastasis of 
cholangiocarcinoma. 
In summary, CD151 was highly expressed in cancer stem-like cells of 
cholangiocarcinoma and the cancer stem cell properties such as self-renewal 
and chemoresistance were weakened when CD151 was knocked down. The 
related pathway and molecules between CD151 and cholangiocarcinoma stem-
like cells might be c-Met, PI3K, EMT pathway, β-catenin and Oct4, and
CD151 might control the proliferation and metastasis of cholangiocarcinoma. 
V. CONCLUSION
This study demonstrates that CD151 was more expressed in 
cholangiocarcinoma stem-like cells and regulated self-renewal, 
chemoresistance, proliferation and metastatic capabilities. It interacted with 
c-Met, PI3K/AKT, EMT pathway, β-catenin, and Oct4, and resulted in having 
cancer stem cell-like properties. Therefore, CD151 should be considered as a 
potential molecular marker of cholangiocarcinoma stem cells. It may be expected 
to be a therapeutic target of cholangiocarcinoma stem cells in the future. Further 
studies towards this end are required.
28
REFERENCES
1. Steiner PE, Higginson J. Cholangiolocellular carcinoma of the liver. Cancer 
1959;12:753-9.
2. Morise Z, Sugioka A, Hoshimoto S, Kato T, Tanahashi Y, Ikeda M, et al. 
Patient with advanced intrahepatic cholangiocarcinoma with long-term survival 
successfully treated with a combination of surgery and chemotherapy. J 
Hepatobiliary Pancreat Surg 2008;15:545-8.
3. Igami T, Nishio H, Ebata T, Yokoyama Y, Sugawara G, Nimura Y, et al. 
Surgical treatment of hilar cholangiocarcinoma in the “new era”: the Nagoya 
University experience. J Hepatobiliary Pancreat Sci 2010;17:449-54.
4. Bonnet D, Dick JE. Human acute myeloid leukemia is organized as a 
hierarchy that originates from a primitive hematopoietic cell. Nat Med 
1997;3:730-7.
5. Alison MR, Lim SM, Nicholson LJ. Cancer stem cells: problems for therapy? 
J Pathol 2011;223:148-62.
6. Reya T, Morrison SJ, Clarke MF, Weissman IL. Stem cells, cancer, and 
cancer stem cells. Nature 2001;414:105-11.
7. Sell S, Dunsford H. Evidence for the stem cell origin of hepatocellular 
carcinoma and cholangiocarcinoma. Am J Pathol 1989;134:1347-63.
8. Chiba T, Zheng YW, Kita K, Yokosuka O, Saisho H, Onodera M, et al.
Enhanced self-renewal capability in hepatic stem/progenitor cells drives cancer 
initiation. Gastroenterology 2007;133:937-50.
9. Fan L, He F, Liu H, Zhu J, Liu Y, Yin Z, et al. CD133: a potential indicator 
for differentiation and prognosis of human cholangiocarcinoma. BMC cancer 
2011;11:320.
10. Wang M, Xiao J, Jiang J, Qin R. CD133 and ALDH may be the molecular 
markers of cholangiocarcinoma stem cells. Int J Cancer 2011;128:1996-7.
11. Shimada M, Sugimoto K, Iwahashi S, Utsunomiya T, Morine Y, Imura S, et 
29
al. CD133 expression is a potential prognostic indicator in intrahepatic 
cholangiocarcinoma. J Gastroenterol 2010;45:896-902.
12. Leelawat K, Thongtawee T, Narong S, Subwongcharoen S, Treepongkaruna 
S. Strong expression of CD133 is associated with increased cholangiocarcinoma 
progression. World J Gastroenterol 2011;17:1192-8.
13. Agrawal S, Kuvshinoff BW, Khoury T, Yu J, Javle MM, LeVea C, et al. 
CD24 expression is an independent prognostic marker in cholangiocarcinoma. J
Gastrointest Surg 2007;11:445-51.
14. Su MC, Hsu C, Kao HL, Jeng YM. CD24 expression is a prognostic factor 
in intrahepatic cholangiocarcinoma. Cancer Lett 2006;235:34-9..
15. Keeratichamroen S, Leelawat K, Thongtawee T, Narong S, Aegem U, 
Tujinda S, et al. Expression of CD24 in cholangiocarcinoma cells is associated 
with disease progression and reduced patient survival. Int J Oncol
2011;39:873-81.
16. Boer CJ, Krieken JH, Janssen‐van Rhijn CM, Litvinov SV. Expression of 
Ep‐CAM in normal, regenerating, metaplastic, and neoplastic liver. J Pathol 
1999;188:201-6.
17. Maecker H, Todd S, Levy S. The tetraspanin superfamily: molecular
facilitators. FASEB J 1997;11:428-42.
18. Sincock PM, Mayrhofer G, Ashman LK. Localization of the transmembrane 
4 superfamily (TM4SF) member PETA-3 (CD151) in normal human tissues: 
comparison with CD9, CD63, and alpha5beta1 integrin. J Histochem Cytochem 
1997;45:515-25.
19. Zöller M. Tetraspanins: push and pull in suppressing and promoting 
metastasis. Nat Rev Cancer 2008;9:40-55.
20. Kohno M, Hasegawa H, Miyake M, Yamamoto T, Fujita S. CD151 
enhances cell motility and metastasis of cancer cells in the presence of focal 
adhesion kinase. Int J Cancer 2002;97:336-43.
21. Ke AW, Shi GM, Zhou J, Wu FZ, Ding ZB, Hu MY, et al. Role of 
30
overexpression of CD151 and/or c‐Met in predicting prognosis of hepatocellular 
carcinoma. Hepatology 2009;49:491-503.
22. Tokuhara T, Hasegawa H, Hattori N, Ishida H, Taki T, Tachibana S, et al. 
Clinical significance of CD151 gene expression in non-small cell lung cancer. 
Clin Cancer Res 2001;7:4109-14.
23. Hashida H, Takabayashi A, Tokuhara T, Hattori N, Taki T, Hasegawa H, et 
al. Clinical significance of transmembrane 4 superfamily in colon cancer. Br J 
Cancer 2003;89:158-67.
24. Zhu GH, Huang C, Qiu ZJ, Liu J, Zhang ZH, Zhao N, et al. Expression and 
prognostic significance of CD151, c-Met, and integrin alpha3/alpha6 in 
pancreatic ductal adenocarcinoma. Dig Dis Sci 2011;56:1090-8.
25. Suzuki S. Prognostic significance of CD151 expression in esophageal 
squamous cell carcinoma with aggressive cell proliferation and invasiveness. 
Ann Surg Oncol 2011;18:888-93.
26. Kwon M, Park S, Choi J, Oh E, Kim Y, Park Y, et al. Clinical significance 
of CD151 overexpression in subtypes of invasive breast cancer. Br J Cancer 
2012;106:923-30.
27. Voss M, Gordon N, Maloney S, Ganesan R, Ludeman L, McCarthy K, et al. 
Tetraspanin CD151 is a novel prognostic marker in poor outcome endometrial 
cancer. Br J Cancer 2011;104:1611-18.
28. Shi GM, Ke AW, Zhou J, Wang XY, Xu Y, Ding ZB, et al. CD151 
modulates expression of matrix metalloproteinase 9 and promotes 
neoangiogenesis and progression of hepatocellular carcinoma. Hepatology 
2010;52:183-96.
29. Yang YM, Zhang ZW, Liu QM, Sun YF, Yu JR, Xu WX. Overexpression 
of CD151 predicts prognosis in patients with resected gastric cancer. PLoS One 
2013;8:e58990.
30. Huang XY, Ke AW, Shi GM, Ding ZB, Devbhandari RP, Gu FM, et al. 
Overexpression of CD151 as an adverse marker for intrahepatic 
31
cholangiocarcinoma patients. Cancer 2010;116:5440-51.
31. Sterk LM, Geuijen CA, Berg JG, Claessen N, Weening JJ, Sonnenberg A. 
Association of the tetraspanin CD151 with the laminin-binding integrins α 3β1, 
α6β1, α6β4 and α7β1 in cells in culture and in vivo. J Cell Sci 
2002;115:1161-73.
32. Winterwood NE, Varzavand A, Meland MN, Ashman LK, Stipp CS. A 
critical role for tetraspanin CD151 in α3β1 and α6β4 integrin–dependent tumor 
cell functions on laminin-5. Mol Biol Cell 2006;17:2707-21.
33. Fei Y, Wang J, Liu W, Zuo H, Qin J, Wang D, et al. CD151 promotes 
cancer cell metastasis via integrins α3β1 and α6β1 in vitro. Mol Med Rep 
2012;6:1226-30.
34. Yang W, Li P, Lin J, Zuo H, Zuo P, Zou Y, et al. CD151 promotes 
proliferation and migration of PC3 cells via the formation of CD151-integrin 
α3/α6 complex. J Huazhong Univ Sci Technolog Med Sci 2012;32:383-8.
35. Franco M, Muratori C, Corso S, Tenaglia E, Bertotti A, Capparuccia L, et al. 
The tetraspanin CD151 is required for Met-dependent signaling and tumor cell 
growth. J Biol Chem 2010;285:38756-64.
36. Ke AW, Shi GM, Zhou J, Huang XY, Shi YH, Ding ZB, et al. CD151 
amplifies signaling by integrin α6β1 to PI3K and induces the 
epithelial–mesenchymal transition in HCC Cells. Gastroenterology 
2011;140:1629-41.
37. Jung DE, Wen J, Oh T, Song SY. Differentially expressed microRNAs in 
pancreatic cancer stem cells. Pancreas 2011;40:1180-87.
38. Boccaccio C, Comoglio PM. Invasive growth: a MET-driven genetic 
programme for cancer and stem cells. Nat Rev Cancer 2006;6:637-45.
39. Eder JP, Wounde GFV, Boerner SA, LoRusso PM. Novel therapeutic 
inhibitors of c-MET signaling pathway in cancer. Clin Cancer Res 
2009;15(7):2207-14. 
40. Huang FI, Chen YL, Channg CN, Yuan RH, Jeng YM. Hepatocyte growth 
32
factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate 
tumor invasion. Carcinogenesis 2012;33(6):1142-1148. 
41. Oshima Y, Suzuki A, Kawashimo K, Ishikawa M, Ohkohchi N, Taniguchi 
H. Isolation of mouse pancreatic ductal progenitor cells expressing CD133 and 
c-Met by flow cytometric cell sorting. Gastroenterology 2007;132:720-32. 48 
42. Li C, Wu JJ, Hynes M, Dosch J, Sarkar B, Welling TH, et al. c-MET is a 
marker of pancreatic cancer stem cells and therapeutic target. Gastroenterology 
2011;141:2218-27. 
43. Varnholt H, Asayama Y, Aishima S, Tagucji K, Sugimachi K, Tsuneyoshi 
M. c-Met and hepatocyte growth factor expression in combined hepatocellular 
carcinoma and cholangiocrcinoma. Oncol Rep 2002;9:35-41. 
44. Terada T, Nakanuma Y, Sirica AE. Immunohistochemical demonstration of 
MET overexpression in human intrahepatic cholangiocarcinoma and in 
hepatolithiasis. Hum Pathol 1998;29:175-80. 
45. Sanada Y, Osada S, Tokuyama Y, Tanaka Y, Takahashi T, Yamaguchi K. 
Critical role of c-Met and Ki67 in progress of biliary carcinoma. Am Surg 
2010;76(4):372-9. 
46. Miyamoto M, Ojima H, Iwasaki M, Shimizu H, Kokubu A, Hiraoka N, et al. 
Prognostic significance of overexpression of c-MET oncoprotein in 
cholangiocarcinoma. Bri J Cancer 2011;105:131-8.
47. Teng Y, Wang X, Wang Y, Ma D. Wnt/β-catenin signaling regulates cancer 
stem cells in lung cancer A549 cells. Biochem Biophys Res Commun
2010;392:373-9.
48. Dai X, Ge J, Wang X, Qian X, Zhang C, Li X. OCT4 regulates 
epithelial-mesenchymal transition and its knockdown inhibits colorectal cancer 
cell migration and invasion. Oncol Rep 2013;29:155-60.
49. Ang J, Fang BL, Ashman LK, Frauman AG. The migration and invasion of 
human prostate cancer cell lines involves CD151 expression. Oncol Rep 
2010;24:1593-97.
33
ABSTRACT(IN KOREAN)
담도암 줄기 세포의 분자표지자로서 가능성 있는 CD151
<지도교수 송 시 영 >
연세대학교 대학원 의학과
전 태 주
최근 암줄기 세포가 다양한 암에서 종양형성, 전이, 재발, 
항암제내성을 일으킨다고 가정하고 있다.
CD151은 transmembrane 4 superfamily의 하나로 세포의 이동뿐
아니라 암세포의 침습이나 전이에 관여한다. 간내 담도암에서
CD151과 c-Met의 과발현이 암의 침습과 전이와 연관이 있어
불량 예후를 보인다는 연구와 같이 담도암에서 CD151의 역할에
대한 연구는 있었으나 담도암 줄기세포에서의 역할에 대한
연구는 현재 없다. 이에 본 연구에서는 CD151의 담도암
줄기세포에서 역할을 대해서 알아보고자 하였다. 
담도암 줄기세포에 대한 평가를 위해 본 연구에서는 2개의
담도암 세포주(SNU-245, SNU-1196)를 이용하여 tumorsphere를
배양하여 담도암 줄기 양 세포를 얻었다. cDNA microarray를
이용하여 tumorsphere와 담도암에서 과발현된 유전자를 얻었다. 
Tumorsphere가 줄기세포의 특성을 갖는 지를 보기 위해
RT-PCR과 western blot을 통하여 줄기세포 관련 mRNA와
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c-Met과 EMT 관련 단백질을 확인하였다. CD151의 발현을
SNU-1196 세포주의 부착 세포와 tumorsphere에서 비교하였다. 
CD151의 담도암 줄기 세포에서의 역할을 확인하기 위하여
SNU-1196을 CD151 siRNA로 처리하여 CD151 발현을 억제한
후에 sphere formation assay, cytotoxicity assay를 시행하였다. 또한
c-Met, EMT pathway 관련 인자 및 β-catenin, Oct4의 발현을
western blot을 통하여 확인하였으며 proliferation assay 및
migration assay를 시행하였다. 
결과적으로 cDNA microarray에서 CD151이 tumorsphere와
담도암 모두에서 과발현됨을 알 수 있었다. 배양된 tumor 
sphere는 RT-PCR에서 줄기세포와 관련된 Notch, Hedgehog, Wnt 
관련 인자들이 과발현되고 있고, western blot에서 c-Met, PI3K, 
EMT 관련 인자, β-catenin, Oct4의 발현이 증가되어 있어서
암줄기 세포의 특성을 가지고 있었다. CD151은 부착 세포보다
tumorsphere에서 발현이 더 증가되어 있었다. CD151의 발현을
억제하는 경우 tumorsphere 형성이나 chemoresistance가 감소하는
것으로 보아 CD151을 억제하는 경우 암줄기 세포의 특성이
사라짐을 볼 수 있었다. CD151을 SNU-1196 세포주에서 억제한
후 c-Met, PI3K, EMT 관련 인자, β-catenin, Oct4 모두 발현이
감소하는 것으로 볼 때 CD151은 이들을 통해서 작용을 함을
생각해 볼 수 있었다. 또한 CD151 억제 시 proliferation과
migration이 모두 감소하는 것을 확인할 수 있었다. 
결론적으로 CD151은 담도암줄기 양 세포에서 발현이
증가되어 있었으며 자가재생, 항암제내성, 증식, 전이능력을
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조절하였다. c-Met과 상호 작용을 하여 PI3K 및 EMT pathway, 
β-catenin, Oct4를 활성화시켜 작용을 하는 것으로 생각된다. 
따라서, CD151은 담도암 줄기세포와 관련된 인자로 생각되며
지며 향후 진단적 혹은 치료적 표지자로 이용될 수 있는 중요한
인자로 기대해 볼 수 있겠다. 
----------------------------------------------------------------------------------------
핵심되는 말: CD151, 담도암 줄기세포, c-Met
